home / stock / cue / cue articles
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-exp...
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class ...
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class...
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern arou...
News, Short Squeeze, Breakout and More Instantly...
Cue Biopharma Inc. Company Name:
CUE Stock Symbol:
NASDAQ Market:
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas...
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at...
2024-04-09 12:15:02 ET Oppenheimer analyst issues UNDERPERFORM recommendation for CUE on April 9, 2024 10:01AM ET. The previous analyst recommendation was Underperform. CUE was trading at $1.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...